The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Established targeted therapies, such as Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor…
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…
The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…